Alumis Upgraded to Buy on Psoriasis Data, But DeepValue Report Warns of Overvaluation and Structural Risks

What happened

Alumis Inc. received a Buy upgrade from Seeking Alpha based on strong Phase 3 data for its oral TYK2 inhibitor envudeucitinib in psoriasis, showing 74% PASI 75 and 59% sPGA 0/1 at week 16, comparable to Johnson & Johnson's newly approved Icotyde. The company plans an NDA submission in the second half of 2026, with additional data expected in psoriatic arthritis and systemic lupus erythematosus later that year. However, the DeepValue master report reveals that the stock has already surged from around $5 to $24.17, pricing in much of this success and leaving limited upside at a ~$2.5 billion market cap. Critical risks persist, including a high annualized cash burn of approximately $400 million, twice-daily dosing versus once-daily competitors like Takeda's zasocitinib, and unresolved long-term safety concerns beyond 24 weeks. While the upgrade reflects near-term optimism, the fundamental valuation lacks margin of safety against potential regulatory delays, competitive erosion, or disappointing lupus data in Q3 2026.

Implication

The Buy upgrade highlights envudeucitinib's competitive efficacy but fails to address deeper structural issues outlined in the DeepValue report, such as Alumis's twice-daily dosing putting it at a convenience disadvantage against once-daily oral therapies from larger rivals. With no product revenue and an annualized cash burn of ~$400 million, the company remains reliant on dilutive capital raises, threatening shareholder value if execution stumbles. Upcoming catalysts, including lupus Phase 2b data in Q3 2026, are high-stakes events that could severely impact the multi-indication thesis if negative. Competition from Takeda and J&J, with their superior commercial scale, may cap market share and pricing power, limiting revenue potential. Therefore, investors should avoid new positions at current levels and consider trimming, waiting for a price reset below $17 or clearer evidence of sustainable differentiation before engaging.

Thesis delta

The positive Phase 3 data reinforce envudeucitinib's approval prospects, slightly boosting the bull case probability, but do not materially alter the DeepValue thesis of overvaluation and high risk. Core concerns—such as twice-daily dosing, fierce competition, and unresolved safety—remain unaddressed, and the stock's rally may have prematurely discounted success without pricing in financial or competitive headwinds. No shift in the 'POTENTIAL SELL' rating is justified until either the price corrects meaningfully or new data demonstrate durable advantages beyond current expectations.